211 SAMENVATTING 16. Joosten LPT, Van Doorn S, Hoes AW, Nierman MC, Wiersma NM, Koek HL, et al. Safety of switching from Vitamin K antagonist to non-Vitamin K antagonist oral anticoagulant in frail elderly with atrial fibrillation: Rationale and design of the FRAIL-AF randomised controlled trial. BMJ Open. 2019;9(12):e032488. 17. Steverink N, Slaets J, Schuurmans H, van Lis M. Measuring frailty: Developing and testing the GFI (Groningen Frailty Indicator). Gerontologist. 2001;41(1):236–7. 18. Schulman S, Kearon C. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. Journal of Thrombosis and Haemostasis. 2005;3(4):692–4. 19. Kaatz S, Ahmad D, Spyropoulos AC, Schulman S. Definition of clinically relevant nonmajor bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: Communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis. 2015;13(11):2119–26. 20. Joosten LPT, van Doorn S, van de Ven PM, Köhlen BTG, Nierman MC, Koek HL, et al. Safety of switching from a vitamin K antagonist to a non-vitamin K antagonist oral anticoagulant in frail older patients with atrial fibrillation: Results of the FRAIL-AF randomized controlled trial. Circulation. 2024;149(4):279–89. 21. Steinberg B, Washam J. Appropriate dosing of nonvitamin K antagonist oral anticoagulants for stroke prevention in atrial fibrillation. Trends in Cardiovasc Med. 2017;27(8):567–72. 22. Pokorney S, Peterson E, Piccini J. When less is not more. J Am Coll Cardiol. 2017;69(23):2791–3. 23. van Vugt S, Brouwer M, Verheugt F. Off-label use of non-vitamin K antagonist oral anticoagulants. J Am Coll Cardiol. 2017;69:2577–8. 24. Weitz J, Eikelboom J. Appropriate apixaban dosing: Prescribers take note. JAMA Cardiol. 2016;1(6):635–6. 25. Shen NN, Zhang C, Hang Y, Li Z, Kong LC, Wang N, et al. Real-world prevalence of direct oral anticoagulant off-label doses in atrial fibrillation: An epidemiological meta-analysis. Front Pharmacol. 2021;12:581293. 26. Joosten LPT, Van Maanen R, Van Den Dries CJ, Rutten FH, Hoes AW, Granger CB, et al. Clinical consequences of off-label reduced dosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: A systematic review and meta-analysis. Open Heart. 2023;10(1):e002197. 27. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Eng J Med. 2009;361(12):1139–51. 28. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Eng J Med. 2011;365(10):883–91. 29. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Eng J Med. 2011;365(11):981–92. 30. Giugliano RP, Ruff CT, Braunwald E, Murphy SA, Wiviott SD, Halperin JL, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Eng J Med. 2013;369(22):2093–104. A
RkJQdWJsaXNoZXIy MTk4NDMw